Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- About
Maze Therapeutics, Inc. Common Stock (MAZE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: MAZE (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
Analysis of Past Performance
Type Stock | Historic Profit -12.21% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 525.32M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 6.71 - 17.00 | Updated Date 05/17/2025 |
52 Weeks Range 6.71 - 17.00 | Updated Date 05/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.42 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 32.97% | Operating Margin (TTM) -969.16% |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 454876736 | Price to Sales(TTM) 3.14 |
Enterprise Value 454876736 | Price to Sales(TTM) 3.14 | ||
Enterprise Value to Revenue 2.72 | Enterprise Value to EBITDA 6.71 | Shares Outstanding 43777000 | Shares Floating 9631077 |
Shares Outstanding 43777000 | Shares Floating 9631077 | ||
Percent Insiders 11.49 | Percent Institutions 56.82 |
Upturn AI SWOT
Maze Therapeutics, Inc. Common Stock
Company Overview
History and Background
Maze Therapeutics is a biopharmaceutical company focused on developing precision medicines for genetically defined diseases. Founded in 2019, it leverages advanced data science techniques to identify disease-modifying genes and develop targeted therapies. They completed their IPO in 2023.
Core Business Areas
- Precision Medicines Development: Focuses on identifying and developing therapies for genetically defined diseases with high unmet medical needs.
- Data Science Platform: Utilizes data science and computational biology to identify and validate novel drug targets.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
Leadership and Structure
The leadership team includes Jason Coloma, PhD, as CEO. The organizational structure is typical of a clinical-stage biopharmaceutical company, with departments focused on research and development, clinical operations, and commercialization.
Top Products and Market Share
Key Offerings
- MZE001: An oral glycogen synthase (GYS1) inhibitor in clinical development for Pompe disease. Currently in Phase 1/2 trials. Market share is currently 0 as it is still in development. Competitors in the Pompe disease treatment space include Sanofi (Genzyme) with Lumizyme and Nexviazyme.
- Target Discovery Programs: Early stage programs leveraging their COMPASS platform to identify novel targets for genetically defined diseases. Market share is not applicable due to the early stage. Competitors include other biotech companies with similar discovery platforms.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, long development timelines, and stringent regulatory requirements. Precision medicine is a growing area, with increasing emphasis on genetically targeted therapies.
Positioning
Maze Therapeutics is positioned as a precision medicine company using advanced data science to identify and develop novel therapies. Its competitive advantage lies in its COMPASS platform and focus on genetically defined diseases.
Total Addressable Market (TAM)
The total addressable market for genetically defined diseases is estimated to be substantial and growing, potentially reaching billions of dollars across various indications. Maze's success depends on the number of diseases it targets with FDA approved treatments.
Upturn SWOT Analysis
Strengths
- Proprietary COMPASS data science platform
- Focus on genetically defined diseases with high unmet needs
- Experienced management team
- Strong investor backing
Weaknesses
- Limited number of clinical-stage programs
- High cash burn rate
- Reliance on successful clinical trial outcomes
- Dependent on collaboration for research and funding.
Opportunities
- Expansion of pipeline through new target discovery
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results leading to regulatory approvals
- Advancements in precision medicine technologies
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other biopharmaceutical companies
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- SNY
- GILD
- BMY
Competitive Landscape
Maze Therapeutics faces competition from larger pharmaceutical companies with established presence in rare disease treatments. Its competitive advantage lies in its data science approach and focus on genetically defined diseases.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to the company's recent founding. Growth has been mainly in terms of pipeline expansion and financing.
Future Projections: Future growth is dependent on the success of MZE001 in Pompe disease and other pipeline programs. Analyst estimates vary widely based on clinical trial outcomes and regulatory approvals.
Recent Initiatives: Recent initiatives include advancing MZE001 into later-stage clinical trials and expanding the target discovery platform.
Summary
Maze Therapeutics is a clinical-stage company in a competitive landscape with a focus on precision medicine. Its strengths lie in its proprietary platform and experienced leadership. The company's success is dependent on positive clinical trial outcomes and ability to navigate regulatory hurdles. Their cash burn rate is high and the company needs to demonstrate positive signals in the coming quarters to maintain investor confidence.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Financial data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Maze Therapeutics, Inc. Common Stock
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2025-01-31 | CEO & Director Dr. Jason V. Coloma M.B.A., M.P.H., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 125 | Website https://www.mazetx.com |
Full time employees 125 | Website https://www.mazetx.com | ||
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is in phase I clinical trial for the treatment of chronic kidney disease. The company also offers MZE001, a clinical program for the treatment of Pompe disease. Maze Therapeutics, Inc. was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.